TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27540967

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise and Cognitive Training Combined (AECT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cognitive Training (CT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No Treatment (NT)
Number of subjects: 80
Study: 25551814

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block with 150 mg levobupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no paravertebral block)
Number of subjects: 40
Study: 22038338

Group type: EXPERIMENTAL
Intervention: Internet training (behaviorally focused and video-based training, 2 weekly visits)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 158
Study: 20567823

Group type: EXPERIMENTAL
Intervention: Hospira filgrastim at 5 microg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hospira filgrastim at 10 microg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amgen filgrastim at 5 microg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amgen filgrastim at 10 microg/kg
Number of subjects: 50
Study: 18950331

Group type: EXPERIMENTAL
Intervention: Caudal blockade with levobupivacaine 0.25% 2 mg x kg(‐1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Balanced general anesthesia with remifentanil
Number of subjects: 62
Study: 16022917

Group type: COMPARATOR
Intervention: Vinorelbine 30 mg/m² D1,8 with Carboplatin AUC 5 D1 (VC)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m² with Gemcitabine 1000 mg/m² (VG)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Vinorelbine 30 mg/m² with Carboplatin (VC)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m² with Gemcitabine (VG)
Number of subjects: 316
Study: 12955634

Group type: EXPERIMENTAL
Intervention: 750 mg levofloxacin per day for 5 days
Number of subjects: 390

Group type: COMPARATOR
Intervention: 500 mg levofloxacin per day for 10 days
Number of subjects: 390
Study: 10618536

Group type: EXPERIMENTAL
Intervention: MMR-Vax(R)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Pluserix(R)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Triviraten(R)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: MMR-Vax(R) and Pluserix(R) (revaccination)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Low-level antibodies (defined as 0.15<0.40 IU/ml for measles, 1:230<=1:500 for mumps, and 7-16 IU/ml for rubella)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Low-level antibodies
Number of subjects: 766
Study: 8692415

Group type: EXPERIMENTAL
Intervention: Extensive peridural scar
Number of subjects: 197

Group type: COMPARATOR
Intervention: Less extensive peridural scar
Number of subjects: 197
Study: 1802186

Group type: EXPERIMENTAL
Intervention: Spontaneous feeding without energy-dense food promotion
Number of subjects: 88

Group type: COMPARATOR
Intervention: Meals before spontaneous feeding instructions
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Meals after spontaneous feeding instructions
Number of subjects: 88
Study: 6351957

Group type: EXPERIMENTAL
Intervention: sulphamethoxazole 1000 mg twice daily for 7 days
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: trimethoprim (160 mg)‐sulphamethoxazole (800 mg) (TMP‐SMX) twice daily for 7 days
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: sulphamethoxazole
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: trimethoprim alone
Number of subjects: 109
Study: 30894442

Group type: EXPERIMENTAL
Intervention: Genetically predicted age at puberty (1-year increase)
Number of subjects: 329245

Group type: EXPERIMENTAL
Intervention: Multivariable MR analysis controlling for adult BMI
Number of subjects: 329245

Group type: EXPERIMENTAL
Intervention: Incorporation of childhood BMI in multivariable MR analysis
Number of subjects: 329245
Study: 30015550

Group type: EXPERIMENTAL
Intervention: Li quick repositioning maneuver
Number of subjects: 120

Group type: COMPARATOR
Intervention: Barbecue repositioning maneuver
Number of subjects: 120
Study: 27567423

Group type: EXPERIMENTAL
Intervention: F(ab)2 antivenom
Number of subjects: 21
Study: 24064386

Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22119854

Group type: EXPERIMENTAL
Intervention: Cartomerge
Number of subjects: 97

Group type: COMPARATOR
Intervention: NavX Fusion
Number of subjects: 97
Study: 19419338

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 110 microg once daily
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 17484585

Group type: EXPERIMENTAL
Intervention: Stereotype threat made salient by reminding participants of male achievement in mathematics (Experiment 1)
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Stereotype threat (Experiment 2)
Number of subjects: 747
Study: 14694242

Group type: EXPERIMENTAL
Intervention: Fluticasone (1500 microg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Budesonide (1600 microg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fluticasone and Budesonide
Number of subjects: 18
Study: 16290729

Group type: EXPERIMENTAL
Intervention: Prototype blackcurrant drink
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toothkind blackcurrant drink
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mineral water
Number of subjects: 0
Study: 10505557

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin plus intermittent intraperitoneal (IP) vancomycin
Number of subjects: 101

Group type: COMPARATOR
Intervention: IP netromycin plus intermittent IP vancomycin
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin plus intermittent IP vancomycin
Number of subjects: 101
Study: 8089288

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (3 MU subcutaneously three times per week, increased to 12 MU, total dose of 216 MU over 2 months)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (9 MU once a month continued in half the patients)
Number of subjects: 14
Study: 2684306

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intravenous acyclovir
Number of subjects: 27
Study: 57444

Group type: EXPERIMENTAL
Intervention: Fractionated insulin preparations (Nordisk Insulin Ltd)
Number of subjects: 6
Study: 31037340

Group type: EXPERIMENTAL
Intervention: Soy-based ready-to-use therapeutic food (S-RUTF)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Milk-based ready-to-use therapeutic food (M-RUTF)
Number of subjects: 260
Study: 30506579

Group type: EXPERIMENTAL
Intervention: ACh (endothelium-dependent dilator) during exercise
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP; endothelium-independent dilator) during exercise
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: KCl infusion in quiescent muscle
Number of subjects: 7
Study: 28984822

Group type: EXPERIMENTAL
Intervention: Walnut-enriched diet (43 g walnuts/day)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control (nut-free diet)
Number of subjects: 194
Study: 26039534

Group type: EXPERIMENTAL
Intervention: Candesartan treatment for 7 days, lowering blood pressure by 5/2 mmHg from day 2 onwards.
Number of subjects: 2029

Group type: COMPARATOR
Intervention: Placebo control group.
Number of subjects: 2029
Study: 23672632

Group type: EXPERIMENTAL
Intervention: linagliptin added to metformin and sulphonylurea
Number of subjects: 192

Group type: COMPARATOR
Intervention: placebo added to metformin and sulphonylurea
Number of subjects: 192
Study: 21742842

Group type: EXPERIMENTAL
Intervention: Aerosol EZ measles vaccine for 2.5 minutes
Number of subjects: 113

Group type: COMPARATOR
Intervention: Subcutaneous measles vaccine
Number of subjects: 113
Study: 18569468

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (Enoxaparin sodium 0.2 ml, 20 mg, once daily subcutaneously)
Number of subjects: 340

Group type: COMPARATOR
Intervention: No treatment (folic acid tablets 0.5 mg daily until 13 weeks gestation)
Number of subjects: 340
Study: 17127550

Group type: EXPERIMENTAL
Intervention: GABA medications
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Adrenergic blockers
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low withdrawal severity
Number of subjects: 85
Study: 14679156

Group type: EXPERIMENTAL
Intervention: Once daily tobramycin (n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Every 8 hours tobramycin (n = 31)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Once daily tobramycin (n = 26)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Every 8 hours tobramycin (n = 27)
Number of subjects: 60
Study: 10946430

Group type: EXPERIMENTAL
Intervention: Community intervention to reduce delay in MI symptoms to hospital arrival
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 10
Study: 9505990

Group type: EXPERIMENTAL
Intervention: Butorphanol nasal spray (1 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of butorphanol nasal spray (1 mg) and metoclopramide (10 mg)
Number of subjects: 24
Study: 8489831

Group type: EXPERIMENTAL
Intervention: Ionic contrast media
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ionic contrast media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-registration trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-marketing surveillances
Number of subjects: 0
Study: 3789297

Group type: EXPERIMENTAL
Intervention: Local anesthetic injection of carotid sinus nerve with bupivacaine (Marcaine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No injection (Control)
Number of subjects: 100
Study: 29743322

Group type: EXPERIMENTAL
Intervention: Care for Stroke intervention
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 266
Study: 27742226

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF (Tenofovir Alafenamide)
Number of subjects: 200

Group type: COMPARATOR
Intervention: E/C/F/TDF (Tenofovir Disoproxil Fumarate)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combined groups (TAF and TDF)
Number of subjects: 200
Study: 24667300

Group type: EXPERIMENTAL
Intervention: Dacarbazine (Dac) with oblimersen sodium (7 mg/kg/day)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Dacarbazine (Dac) with placebo
Number of subjects: 314
Study: 23346662

Group type: EXPERIMENTAL
Intervention: 5% acetylcysteine topical gel
Number of subjects: 99
Study: 20650041

Group type: EXPERIMENTAL
Intervention: Combination therapy of prednisone and leflunomide (LEF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combination therapy of prednisone and mycophenolate mofetil (MMF)
Number of subjects: 40
Study: 18574653

Group type: EXPERIMENTAL
Intervention: artesunate-cotrimoxazole
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine
Number of subjects: 182
Study: 15858606

Group type: EXPERIMENTAL
Intervention: Bubble NCPAP
Number of subjects: 18

Group type: COMPARATOR
Intervention: VF-NCPAP
Number of subjects: 18
Study: 12910485

Group type: EXPERIMENTAL
Intervention: Multivitamin supplements around the time of conception and during early pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folic acid supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11313659

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid - 300 mg/day for 28 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo - twice a day for 28 days
Number of subjects: 40
Study: 8780542

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 418
Study: 1610866

Group type: EXPERIMENTAL
Intervention: OKT3, 5 mg/day for 7 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: ALG, 15 mg/kg/day for 7 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 39

Group type: COMPARATOR
Intervention: ALG
Number of subjects: 39
Study: 6734079

Group type: EXPERIMENTAL
Intervention: Plethysmographic technique for measuring arterial compliance
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Calculation from pulse wave velocity and brachial artery dimension
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Plethysmographic technique
Number of subjects: 31
Study: 30413191

Group type: EXPERIMENTAL
Intervention: Combined-intervention group (one-session individual intervention with detailed information on functioning, activities of daily living, physical activity, nutrition, assistive devices, instructions on pain management and exercises)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Routine-care-plus-placebo group
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Combined-intervention group
Number of subjects: 151
Study: 27428201

Group type: EXPERIMENTAL
Intervention: Tryptophan (1000 mg/d, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 80
Study: 24929461

Group type: EXPERIMENTAL
Intervention: Tai Chi group (n = 24)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Exercise group (n = 24)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Wait-list group (n = 24)
Number of subjects: 72
Study: 23023573

Group type: EXPERIMENTAL
Intervention: Mesh Plug (MP)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Shouldice (S)
Number of subjects: 300
Study: 20934559

Group type: EXPERIMENTAL
Intervention: Darapladib (160 mg enteric-coated tablets)
Number of subjects: 15828

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15828
Study: 18797468

Group type: EXPERIMENTAL
Intervention: ECMF (epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil)
Number of subjects: 2021

Group type: EXPERIMENTAL
Intervention: ECMF
Number of subjects: 2021

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 2021

Group type: COMPARATOR
Intervention: ECMF and CMF
Number of subjects: 2021
Study: 16247099

Group type: EXPERIMENTAL
Intervention: North American ginseng extract (2 capsules per day for 4 months)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo (2 capsules per day for 4 months)
Number of subjects: 279
Study: 12080314

Group type: EXPERIMENTAL
Intervention: Rigid fixation with three 2-mm bicortical position screws
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wire fixation with inferior border wires and 6 weeks of skeletal maxillomandibular fixation with 24-gauge wires
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Rigid and Wire)
Number of subjects: 0
Study: 10207506

Group type: EXPERIMENTAL
Intervention: GH (up to 0.25 U/kg/week in daily doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 20
Study: 7789626

Group type: EXPERIMENTAL
Intervention: Insulin-modified frequently sampled intravenous glucose tolerance test (FSIVGTT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isoglycemic hyperinsulinemic clamp
Number of subjects: 12
Study: 2192563

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day) plus behavior modification
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo plus behavior modification
Number of subjects: 45
Study: 435014

Group type: EXPERIMENTAL
Intervention: peer‐oriented incare
Number of subjects: 466

Group type: COMPARATOR
Intervention: intensive incare
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: network
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: no‐network
Number of subjects: 466
Study: 31990801

Group type: EXPERIMENTAL
Intervention: Prolene explants (cleaned)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Unused ('exemplar') TVT specimens (with and without intentional oxidation)
Number of subjects: 205
Study: 30659676

Group type: EXPERIMENTAL
Intervention: Double anodal tDCS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 15
Study: 28333512

Group type: EXPERIMENTAL
Intervention: Positive affect skills intervention
Number of subjects: 159

Group type: COMPARATOR
Intervention: Attention-matched control condition
Number of subjects: 159
Study: 26005977

Group type: EXPERIMENTAL
Intervention: Gelatin sponge insertion (group A)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Non-insertion (group B)
Number of subjects: 278
Study: 23856015

Group type: EXPERIMENTAL
Intervention: Goal-focused intervention delivered in community pharmacies
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Goal-focused intervention
Number of subjects: 144
Study: 21043792

Group type: COMPARATOR
Intervention: RPc (ridge preservation with primary wound closure)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RPe (ridge preservation without primary wound closure)
Number of subjects: 11
Study: 19285600

Group type: EXPERIMENTAL
Intervention: Resistant starch
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Corn bran
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polydextrose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-fiber muffin (LF)
Number of subjects: 20
Study: 17091752

Group type: EXPERIMENTAL
Intervention: Clean Intermittent Self-Catheterization (CISC) performed 1-4 times/24 hours
Number of subjects: 80

Group type: COMPARATOR
Intervention: Indwelling Catheter with fortnightly catheter change
Number of subjects: 80
Study: 14722148

Group type: EXPERIMENTAL
Intervention: DSEC (dietary supplement containing ephedra [12 mg] and caffeine [40 mg])
Number of subjects: 15
Study: 11552024

Group type: EXPERIMENTAL
Intervention: Cooling garment at 7 degrees C (active cooling)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham cooling at 26 degrees C (control)
Number of subjects: 10
Study: 9756228

Group type: EXPERIMENTAL
Intervention: Practice nurses identifying patients drinking above recommended guidelines
Number of subjects: 1852

Group type: EXPERIMENTAL
Intervention: Referral to GP by practice nurses
Number of subjects: 1852

Group type: EXPERIMENTAL
Intervention: Screening instruments and brief interventions by practice nurses
Number of subjects: 1852
Study: 8147341

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet (Rec diet)
Number of subjects: 21
Study: 3210128

Group type: EXPERIMENTAL
Intervention: Experimental group instructed to fake depression, provided with a clinical description of the disorder, and offered a cash incentive for convincing test display of depression.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not explicitly described in the abstract).
Number of subjects: 58
Study: 31326321

Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) coupled with Expectation Questionnaire-Pgm
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional clinical interview
Number of subjects: 90

Group type: COMPARATOR
Intervention: Shared Decision Making (SDM)
Number of subjects: 90
Study: 28748974

Group type: EXPERIMENTAL
Intervention: Cranberries (40 g)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no cranberries)
Number of subjects: 25
Study: 26053149

Group type: EXPERIMENTAL
Intervention: Higher P3b amplitudes to target stimuli in a go/no-go task
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Children's learning-related behaviors in kindergarten
Number of subjects: 239
Study: 23098414

Group type: EXPERIMENTAL
Intervention: Experimental multilevel intervention designed to improve quality of care and resident outcomes
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Experimental multilevel intervention
Number of subjects: 29
Study: 21725875

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Simple needling (SN)
Number of subjects: 63
Study: 19526433

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) acupuncture
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 89

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 89
Study: 16478842

Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HRV biofeedback with additional training in pursed-lips abdominal breathing
Number of subjects: 45
Study: 15457926

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DN114001 fermented milk (10(8)-10(10) ufc/g), 3 cups per day for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo, 3 cups per day for 8 weeks
Number of subjects: 45
Study: 11679027

Group type: EXPERIMENTAL
Intervention: Clonidine plus Passiflora extract
Number of subjects: 65

Group type: COMPARATOR
Intervention: Clonidine plus placebo
Number of subjects: 65
Study: 9777137

Group type: EXPERIMENTAL
Intervention: Hirudin treatment in patients with ST elevation receiving thrombolytic therapy (TIMI 9)
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Hirudin treatment in the full spectrum of acute coronary syndromes (GUSTO 2)
Number of subjects: 15000
Study: 7932515

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms oral dose
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2892768

Group type: EXPERIMENTAL
Intervention: Nizatidine (300 mg 'nocte')
Number of subjects: 165

Group type: COMPARATOR
Intervention: Ranitidine (300 mg 'nocte')
Number of subjects: 165
Study: 29345532

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) - 3×5-min occlusions with 5-min reperfusion, 15 min prior to sprinting
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Placebo (SHAM) - 15 min prior to sprinting
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 18
Study: 27302544

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioural therapy
Number of subjects: 397

Group type: COMPARATOR
Intervention: Routine postpartum care
Number of subjects: 397
Study: 24145571

Group type: EXPERIMENTAL
Intervention: Topical basic fibroblast growth factor plus oral L‐cysteine supplements (Group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Basic fibroblast growth factor eye drops (Group 2)
Number of subjects: 120
Study: 22978615

Group type: EXPERIMENTAL
Intervention: Diamel (two capsules before each of the three main meals daily for 1 year)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (two capsules before each of the three main meals daily for 1 year)
Number of subjects: 100
Study: 19789920

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen (LN) fundoplication
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Laparoscopic Toupet (LT) fundoplication
Number of subjects: 100